Advances in Malignant Melanoma Treatment: Immunotherapy and Beyond

Malignant melanoma begins in melanocytes, the cells that produce the pigment responsible for skin color. Although melanoma accounts for a smaller share of skin cancers than basal cell or squamous cell carcinoma, it is more likely to spread to lymph nodes or distant organs if not found early. Surgery can cure many localized melanomas, but treatment becomes more complex when the disease cannot be removed completely or has traveled beyond the original skin site.

Progress in melanoma care has been especially rapid because researchers have learned how melanoma cells interact with the immune system and which genetic changes help the cancer grow. Modern treatment may include immunotherapy, drugs aimed at specific tumor mutations, cell-based treatment, radiation, surgery, or carefully selected combinations. The best plan depends on the stage of disease, the tumor’s biology, a person’s health, and prior treatments.

How Immunotherapy Helps the Immune System Recognize Melanoma

The immune system constantly identifies and removes abnormal cells, including some early cancer cells. Melanoma can avoid this surveillance by using molecular signals that restrain immune cells. Immunotherapy is designed to remove some of those restraints, helping immune cells recognize cancer cells as threats and attack them more effectively.

For people diagnosed with this aggressive form of skin cancer, understanding the available malignant melanoma treatment options helps clarify when immunotherapy may be considered alongside surgery and other specialist care.

The most widely used immunotherapies for melanoma are immune checkpoint inhibitors. Checkpoints are normal control systems that prevent immune responses from becoming too strong. Drugs that block PD-1, such as pembrolizumab and nivolumab, release one of these brakes on T cells, the white blood cells that can kill infected or abnormal cells.

Another checkpoint drug, ipilimumab, blocks CTLA-4, a separate control signal involved earlier in T-cell activation. Combining nivolumab with ipilimumab can produce stronger immune activity than a single drug for some people with advanced melanoma. That added activity also raises the chance of serious side effects, so clinicians weigh the possible benefit against the individual’s risks.

Checkpoint inhibitors may be used after surgery for certain higher-risk melanomas, aiming to reduce the chance of recurrence. They are also central treatments for unresectable stage III or stage IV melanoma. Some patients experience long-lasting control of metastatic disease after immunotherapy, which was far less common before these medicines became available.

Matching Targeted Therapy to Tumor Mutations

Not every melanoma is driven by the same genetic changes. Testing a tumor for mutations helps doctors identify treatments that may fit its biology. The most clinically useful example involves the BRAF gene, which is altered in about half of cutaneous melanomas and can send persistent growth signals inside cancer cells.

BRAF inhibitors interrupt that faulty signal, while MEK inhibitors block another step in the same pathway. These drugs are generally given together because the combination works better and helps delay resistance. Common BRAF and MEK inhibitor pairs include dabrafenib with trametinib, encorafenib with binimetinib, and vemurafenib with cobimetinib.

Targeted therapy can often shrink BRAF-mutant melanoma quickly, making it particularly useful when cancer is causing urgent symptoms or growing rapidly. Its effects may not last as long as successful immunotherapy in every patient, because tumor cells can develop alternate routes around the blocked pathway. For this reason, treatment sequencing remains an active area of research and discussion.

These medicines have side effects distinct from those of immunotherapy. Fever, fatigue, rash, sensitivity to sunlight, joint pain, and changes in liver tests can occur, depending on the regimen. Regular monitoring allows the care team to adjust doses, pause treatment, or manage complications while preserving as much benefit as possible.

Cell Therapy Offers a Personalized Immune Approach

Tumor-infiltrating lymphocyte therapy, often called TIL therapy, uses immune cells already found inside a person’s tumor. Scientists remove a tumor sample, isolate T cells that have entered it, and grow very large numbers of those cells in a laboratory. The expanded cells are then returned to the patient, where they are intended to seek out and attack melanoma.

In 2024, the U.S. Food and Drug Administration granted accelerated approval to lifileucel for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking drug and, when appropriate, a BRAF inhibitor. It was the first FDA-approved T-cell therapy for a solid tumor. Its availability marked a meaningful new option for patients whose melanoma has progressed after standard treatments.

TIL therapy is intensive and is delivered at specialized centers. Before the cells are infused, patients receive chemotherapy that reduces existing immune cells and creates room for the incoming T cells. High-dose interleukin-2 is then used to support the transferred cells, but it can cause substantial side effects, including low blood pressure, fever, fluid retention, and strain on organs.

Local Treatments Still Matter in Advanced Disease

Surgery remains the primary treatment for melanoma that is confined to the skin or nearby lymph nodes. In selected cases, surgery can also remove isolated metastatic tumors, especially when the disease is limited and complete removal is feasible. Sentinel lymph node biopsy may help determine whether microscopic melanoma cells have reached nearby lymph nodes and guide decisions about further treatment.

Radiation therapy does not usually replace surgery or systemic therapy for melanoma, but it can be valuable in specific circumstances. It may treat melanoma that has spread to the brain, relieve pain from bone metastases, or reduce the risk of recurrence in certain lymph node areas. Modern techniques can focus radiation more precisely, limiting exposure to surrounding healthy tissue.

Some tumors can be treated directly with injections. Talimogene laherparepvec, also called T-VEC, is an engineered virus injected into melanoma lesions that cannot be removed surgically. It infects and destroys cancer cells locally while also stimulating an immune response. This approach is most relevant when melanoma has accessible skin, subcutaneous, or lymph node lesions.

Brain metastases require especially careful planning because melanoma has a tendency to spread to the brain. Treatment may combine checkpoint inhibitors, focused radiation, surgery, medicines to control swelling, and close imaging follow-up. Decisions are often made by a multidisciplinary team that includes medical oncologists, radiation oncologists, surgeons, radiologists, and other specialists.

Managing Side Effects and Planning Care Over Time

Immunotherapy side effects result from an immune system that becomes overly active and attacks normal tissue. Skin rash, itching, diarrhea, thyroid changes, fatigue, and inflammation of the liver are among the more common problems. Less often, inflammation can affect the lungs, heart, kidneys, nervous system, or hormone-producing glands, requiring urgent assessment and treatment.

Patients should report new symptoms promptly rather than waiting for a routine appointment. Diarrhea, shortness of breath, chest pain, severe headache, confusion, marked weakness, or major changes in vision can signal potentially serious immune-related reactions. Corticosteroids and other immune-suppressing medicines may be used when inflammation is significant, sometimes alongside a temporary or permanent stop in immunotherapy.

Care increasingly focuses on the entire course of illness, not just the first treatment choice. Doctors may repeat scans, monitor blood tests, test tumor tissue, and reassess symptoms to determine whether a treatment is working or causing harm. Clinical trials also remain important, studying personalized cancer vaccines, new immune combinations, medicines that target resistance pathways, and improved ways to identify patients most likely to benefit.

A More Individualized Future for Melanoma Care

Melanoma treatment has moved from a narrow set of options toward individualized care built around tumor genetics, immune response, disease location, and patient priorities. Immunotherapy has transformed outcomes for many people, while targeted drugs, TIL therapy, surgery, radiation, and local injections extend the available choices. Continued research aims to make responses more durable, reduce treatment toxicity, and provide effective options for patients whose melanoma does not respond to current therapies.